The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease
Open accessAbstract
BACKGROUND.: Early prediction of response to therapy may offer the potential to identify patients who will benefit from standard conventional therapy. The objective of this study was to determine the predictive value of FDG‐PET as an early response indicator after 1 cycle of chemotherapy for progression‐free survival (PFS) in diffuse large cell lymphoma (DLCL) and classic Hodgkin disease (HD). METHODS.: FDG‐PET was performed before, after 1 cycle, and after completion of chemotherapy in 47 patients. The patients were followed with a median follow‐up of 21 months (range, 3–47 months). PFS was compared between PET‐positive and PET‐negative patients after 1 cycle and after completion of therapy. RESULTS.: All PET‐negative patients after 1 cycle (n = 31) had sustained complete remission with a median follow‐up of 28 months. Fourteen of 16 PET‐positive patients after 1 cycle had refractory disease or relapsed (median PFS, 5.5 months). There were 2 false‐positive results, 1 with an active infection at the biopsy site and the other in a patient who had been in remission after radiation therapy. There was good agreement between the results obtained after 1 cycle and at completion of therapy (kappa, 0.80); however, the negative predictive value was higher for FDG‐PET after 1 cycle than after completion of chemotherapy (100% vs 91.4%), although not statistically different (P = .40). CONCLUSIONS.: FDG‐PET had a high prognostic value after 1 cycle of chemotherapy, thus it can be a valid alternative for posttreatment evaluation of DLCL and HD and may offer the potential for change in treatment paradigms. Cancer 2006. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf256 · Cited by 410
Cited by
Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Self-citationBarrington, S. F., Qian, W., Somer, E. J., Franceschetto, A., Bagni, B., Brun, E., Almquist, H., Loft, A., Højgaard, L., Federico, M., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1490-5 · Cited by 348
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Biggi, A., Gallamini, A., Chauvie, S., Hutchings, M., Kostakoglu, L., Gregianin, M., Meignan, M., Malkowski, B., Hofman, M. S., & Barrington, S. F. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.110890 · Cited by 311
Self-citationThe role of FDG-PET scans in patients with lymphoma
Seam, P., Juweid, M. E., & Cheson, B. D. (2007) · Blood · doi:10.1182/blood-2007-06-097238 · Cited by 304
Metadata
- Authors
- Kostakoglu, L., Goldsmith, S. J., Leonard, J. P., Christos, P., Furman, R. R., Atasever, T., Chandramouly, A., Verma, S., Kothari, P., & Coleman, M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-10-24
- Volume
- 107
- Issue
- 11
- Pages
- 2678-2687
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2066799536
- Cited by
- 168
- References
- 1
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.